A series of independent, unsupported programs developed by theheart.org featuring discussions with world renowned cardiologists on the importance of the latest clinical trial findings and cardiology news.
All content for Discussions about Cardiology from theheart.org is the property of theheart.org and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A series of independent, unsupported programs developed by theheart.org featuring discussions with world renowned cardiologists on the importance of the latest clinical trial findings and cardiology news.
Discussions about Cardiology from theheart.org: A serious look at GRAVITAS
Discussions about Cardiology from theheart.org
11 minutes 16 seconds
14 years ago
Discussions about Cardiology from theheart.org: A serious look at GRAVITAS
In the GRAVITAS trial, 5429 patients on the regular clopidogrel dose underwent platelet-function tests with the VerifyNow assay (Accumetrics, San Diego, CA) 12 to 24 hours after PCI. Of these, 2214 (41%) had high residual platelet reactivity (platelet reactivity units [PRU] >230) and were randomized to continue on the 75-mg regular clopidogrel dose or to receive another 600-mg loading dose and a higher maintenance dose of 150 mg daily.
Baseline characteristics showed that most patients were at relatively low risk, with 80% having stable coronary artery disease. At six months of follow-up, the composite end point of cardiovascular death/MI/stent thrombosis was identical in both groups, at 2.3%.
heartwire's Sue Hughes sits down with Dr Sunil Rao to talk about the clinical implications of these results and what they mean for the future of platelet-function testing.
Discussions about Cardiology from theheart.org
A series of independent, unsupported programs developed by theheart.org featuring discussions with world renowned cardiologists on the importance of the latest clinical trial findings and cardiology news.
